RFA-CA-27-006: NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required)

RFA-CA-27-006: NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required)

The NCORP Research Bases NOFO is a high-stakes, community-facing clinical-research route funded through the National Cancer Institute. It is aimed at institutions that can run serious cancer prevention, treatment, and care-delivery studies in settings that are closer to where patients are diagnosed and treated.

This is not a broad “idea grant.” It is a systems-focused clinical research mechanism. The NOFO explicitly describes NCORP as a network meant to make clinical trial evidence more generalizable by running studies in a range of community sites and healthcare environments. Research Bases are the program’s central hubs: they are expected to provide leadership, data systems, and operational governance, then support affiliated community and academic sites.

This opportunity is still in the 2026 filing cycle with a key date of September 18, 2026 and review trajectory into 2027, making it relevant for 2026 and 2027 planning.

Key details at a glance

What this NOFO is actually funding

If you read the NOFO purpose statement closely, this is fundamentally about building practical research infrastructure for real-world clinical oncology, with emphasis on cancer control, prevention, screening, care delivery, treatment-adjacent outcomes, and quality-of-life studies embedded in treatment settings. The NOFO says NCORP enhances generalizability by operating in a wide range of community settings rather than only tertiary centers.

The Research Base role is not just another project site. The application is expected to propose a structure that can coordinate research across multiple participating centers and support both trial operations and downstream support functions. This distinction matters because NIH review and implementation burden is tied to the strength of the system, not just scientific novelty in one lab or one clinic.

Why does that matter? Because this NOFO’s internal architecture is clear:

• Research Bases provide the lead scientific and statistical leadership for complex, multi-institution work.
• They host operational support for studies, protocol management, data capture, quality assurance, compliance, and training.
• They connect and strengthen the network model across community environments.

In practice, reviewers typically expect applications that show this is a real hub program, not a single-center pilot repackaged as a network proposal. The NOFO language around protocol development, participant compliance requirements, auditing, and quality assurance is a strong signal: this is an operations-heavy award.

A practical way to think about this category is that it rewards applicants who can answer three questions clearly:

1. Can your organization reliably run and oversee clinical oncology studies at scale?
2. Can you support affiliates with data, compliance, and trial operations?
3. Can your design improve outcomes that generalize beyond an isolated trial center?

Why this is a 2026/2027-relevant opportunity

Most teams in oncology research are trying to time their pipeline around either early-stage discovery or late-stage commercialization. This opportunity sits in an important middle layer: deployment and implementation of cancer research in community environments.

As of the published date and metadata, it is part of a 2026 cycle that leads into 2027 scientific review and start decisions. The NOFO key-date line for this track is explicit: due date in Sep 2026, with review in early 2027 and earliest starts reported in July 2027. That makes it ideal for applicants who can commit to multi-year operations and not just one-time deliverables.

It is also strategically useful for teams already embedded in oncology systems but without a major national center base. The stated NCORP model is to bring trials and support services to representative patients, which can be a better match than center-only translational calls for organizations that are already clinically engaged.

This is especially relevant to institutions that:

• already participate in NCTN-linked ecosystems,
• have demonstrated multi-site coordination capacity,
• and can run ethically compliant trial operations to high regulatory standards.

If your institution is strong in one disease area but weaker in data governance or participant recruitment governance, this is usually not the right first step. The NOFO’s emphasis on centralized scientific leadership and program-level operational maturity means that administrative readiness is evaluated as rigorously as scientific merit.

Eligibility in plain terms

The NOFO and associated section headings indicate NCORP Research Bases are directed at organizations that meet NIH eligibility as a domestic entity and that can meet the functional obligations of a base organization.

The public category list includes:

• For-profit organizations (other than small businesses)
• Small businesses
• Government entities including state and local models
• Education institutions including public/private higher education
• Nonprofits and other nonprofit entities

A practical interpretation is that NIH is not limiting this to universities alone. It is structured to include broader ecosystem participants that can carry a clinical trial infrastructure role. That said, a Research Base has to demonstrate more than legal eligibility; it must show functional capability.

The NOFO and associated listing indicate the general principle that foreign organizations are generally not eligible as principal applicants. Foreign participants/components may have limited pathways in specific operational contexts, but domestic lead status is the practical baseline for this track.

Because this is an NIH NOFO tied to healthcare research operations, teams that can only submit in theory but not in systems readiness should assume they are at high risk. Good applications map their institutional capability directly to NOFO obligations:

• protocol and trial operations governance,
• regulatory compliance capacity,
• training and quality-control workflows,
• data and support infrastructure,
• ability to support community-facing accrual.

Eligibility checklist before any drafting

1. Can your organization be a valid domestic applicant under NIH terms for this NOFO?
2. Can your team document prior multi-site research or clinical operations experience?
3. Do you have institutional systems to manage clinical trial coordination, protocol updates, and quality monitoring?
4. Do you have leadership capacity for statistical and operational direction, not only project-level management?
5. Can you name committed collaborators and affiliate structures for care-delivery and prevention or symptom-management lines?

If any item here is weak, spend budget on strengthening systems before writing your narrative.

How the application process works

The full-text announcement is a standard UG1-style NIH process with three core points: eligibility, compliance readiness, and strict submission instructions.

1) Submit through NIH routes only

The NOFO lists NIH submission options:

• NIH ASSIST system,
• institution-based S2S to Grants.gov plus eRA Commons tracking,
• or Grants.gov Workspace workflow.

Do not treat this as a free-form forms-only program. Even if your partner institution usually handles NIH submissions, make sure your team can align on one route early.

2) Build your narrative around hub capacity

A lot of applicants assume this is “project-first” and lose points because they underplay operational readiness. For this NOFO, operational readiness is part of scientific credibility. Your draft should be explicit on:

• governance model,
• trial operations plan,
• affiliate relationships,
• quality monitoring,
• statistical support,
• how you will convert protocol activity into publication/translation outputs.

The NOFO describes Research Bases as central organizers. That means your narrative should probably use organizational sections that mirror these duties.

3) Keep dates, deadlines, and review timing in one plan

From the published notice line items:

• Posted: May 21, 2026
• Open date: August 18, 2026
• Due date: September 18, 2026
• Expiry: September 19, 2026

Use this timeline as hard planning infrastructure:

• Draft concept by July,
• Internal compliance and pre-review in early August,
• Final internal approvals by late August,
• Buffer period around submission in case institutional systems need correction.

The review and award cycle then proceeds in 2027, which means teams that submit late or with incomplete internal approvals are exposed to avoidable delay.

4) Review readiness must be explicit

The NOFO’s review section clarifies that applications are reviewed in normal peer-review pathways and evaluated by criteria in Section V. You should make this easy for reviewers by structuring the case to map evidence directly to expected judgments:

• problem framing for NCORP,
• fit within cancer prevention/treatment/quality-of-life portfolio,
• scientific and statistical leadership,
• operational feasibility,
• feasibility of participant accrual.

Preparation strategy for teams aiming to win

Most unsuccessful applications on large NIH clinical tracks are not rejected for weak science alone. They often fail because teams treat this like a single-project proposal and underbuild the operational chapter. Here is a practical plan:

Four-week evidence build

Week 1 – Define scope and fit

• Decide if your proposal is primarily prevention, care-delivery, screening, prevention to treatment transition, or symptom-management.
• Confirm that the scientific question connects to NCORP goals and is not too narrow to support a network model.

Week 2 – Build operational narrative

• Draft org chart for trial leadership and support roles.
• Identify data management and compliance owner.
• Specify protocol governance process.

Week 3 – Partner design and accrual model

• Document affiliate sites and referral pathways.
• Clarify what your base contributes versus what affiliates contribute.

Week 4 – Compliance and submission map

• Confirm NIH systems access and institutional signatures.
• Align with eRA Grants.gov/ASSIST office on technical checklists.
• Pre-fill forms and run final internal consistency checks.

Seven common preparation mistakes

1. Treating this as a single lab science grant.
2. Underestimating accrual planning.
3. Lack of statistical and trial operations leadership detail.
4. Ignoring quality-assurance commitments.
5. Weak affiliate coordination narrative.
6. Late internal approvals without buffer for application correction.
7. Not aligning narrative language with NCORP’s prevention/care-delivery objectives.

The strongest applications treat the NOFO as a governance test as much as a science test.

What reviewers typically reward

The NOFO’s review framing and companion sections indicate reviewers look for three hard realities:

• Are the trial operations realistic and scalable?
• Is there clear infrastructure to execute and monitor safety/compliance?
• Is the scientific question meaningful for community-access oncology and likely to produce actionable output?

You should expect reviewers to reward teams that show integrated thinking:

• a trial that is clinically relevant,
• a structure that can coordinate across sites,
• and a realistic plan to support accrual while meeting regulatory standards.

Timeline and applicant prep from announcement to award (high-level)

While implementation timelines depend on review outcomes, the NOFO publishes a clear sequence:

• Aug 18, 2026: earliest submission opens.
• Sep 18, 2026: application due.
• Mar 2027: advisory review and council timing stage (as published in NOFO cycle language).
• Jul 2027: earliest start window.

This sequencing helps teams decide whether to treat the opportunity as a “major” 2026 effort or an immediate 2027 plan:

• Teams with strong internal infrastructure can prepare now and use summer 2026 for compliance heavy lifting.
• Teams with moderate infrastructure should use this cycle mainly to strengthen operations and submit only if they can avoid rushed fixes.

Common questions (short answers)

Is this only for universities and hospitals?

No. The NOFO indicates a range of eligible U.S. organizations, including business, nonprofit, and government categories, with additional NIH Section III requirements.

Is foreign collaboration allowed?

Foreign organizations as primary applicants are generally not eligible; collaboration paths may exist in specific structures, but the lead must satisfy NIH domestic applicant rules.

Is funding guaranteed at a fixed amount per award?

No, the NOFO indicates total program support and expected count, but award values vary by project scope and NIH review outcome.

Does this include both prevention and treatment studies?

Yes, within NCORP’s stated purpose, it includes prevention, cancer control, quality-of-life embedded studies, and care-delivery oriented clinical research.

What is the core thing that makes an application competitive?

Demonstrating you can operate as a real national- or regional-level clinical research base rather than as a thin, single-site proposal.

Practical fit guidance by applicant type

Academic medical centers

If you are a university-affiliated center, this is often a natural fit if your institution has:

• experienced trial operations staff,
• compliance support,
• and a data team that can produce auditable study outputs.

Your competitive edge is often your integration pathways with community affiliates.

Cancer foundations or health systems

These applicants can be strong if they can show:

• sustained research operations,
• governance and oversight,
• and measurable workflow support for affiliates.

What weakens these applications is a strong mission narrative without systems proof.

Government-affiliated entities

Public hospitals and similar public entities can fit if they have mature trial capacity and administrative approvals in place. Without governance maturity, they are unlikely to pass review.

What to keep ready before opening week

You should have at least:

• leadership letters and role clarity,
• data governance and quality assurance plans,
• trial operations flow,
• budget narrative and rationale,
• and evidence of prior coordinated research management.

The official announcement language around protocol development, compliance, auditing, and support to community sites is strict. If your submission gives these a few pages but no implementation details, the reviewers and NIH staff will treat it as underbuilt.

Official links

• Official RFA-CA-27-006 full text (primary source)
• Related NOFO companion components on grants.gov
• NIH How to Apply – Application Guide (for UG1 and NIH routing)

Next action after reading

If this opportunity aligns with your organization, do this now:

1. Build a single-page internal readiness checklist covering compliance, operations, and review-readiness.
2. Confirm your internal applicant status and submission route with your grants office.
3. Identify at least one potential community-affiliate pathway before drafting.
4. Start an internal pre-submission simulation using your intended submission channel.

RFA-CA-27-006 is effectively a “can we run this at the required operational level?” award, not just “can we write a good project description?” If your team can answer yes with evidence, this is one of the better federal pathways for serious oncology translation in community settings.